?-To The Moon - Tiger Brokers Online Investing Community

Like
Comment
Favorite

锐哥来了
2021-07-29

Forbes China's exclusive interview with Xia Yu, Chairman of Akeso Biotech: Take a trip to Hushan Mountain

　　康方生物有限公司创始人、董事长夏瑜向福布斯中国表示：“中国医药创新真正的崛起，必须依靠自身实力，培育创新氛围，打造创新体系，实现创新成果突破。从全球行业发展的商业模式来看，买买买的模式一点问题都没有，但像辉瑞、强生、阿斯利康、诺和诺德这类医药行业领军巨头企业，在国际上有一席之地的医药企业，中国要不要出现？”　　今年4月，康方生物公布了上市后的首份年度成绩单。

Forbes China's exclusive interview with Xia Yu, Chairman of Akeso Biotech: Take a trip to Hushan Mountain

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment

Top
Latest

No comments yet

Most Discussed

{"i18n":{"language":"en_US"},"data":{"magic":2,"id":801885858,"tweetId":"801885858","gmtCreate":1627508922774,"gmtModify":1703491180130,"author":{"id":3583528354923579,"idStr":"3583528354923579","authorId":3583528354923579,"authorIdStr":"3583528354923579","name":"锐哥来了","avatar":"https://static.tigerbbs.com/86eb4f1a6da7a549e0c096e4e1890a8e","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":6,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body>?</body></html>","htmlText":"<html><head></head><body>?</body></html>","text":"?","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://ttm.financial/post/801885858","repostId":2154992231,"repostType":2,"repost":{"id":"2154992231","kind":"news","pubTimestamp":1627378800,"share":"https://ttm.financial/m/news/2154992231?lang=en_US&edition=fundamental","pubTime":"2021-07-27 17:40","market":"sh","language":"zh","title":"Forbes China's exclusive interview with Xia Yu, Chairman of Akeso Biotech: Take a trip to Hushan Mountain","url":"https://stock-news.laohu8.com/highlight/detail?id=2154992231","media":"财经自媒体","summary":"　　康方生物有限公司创始人、董事长夏瑜向福布斯中国表示：“中国医药创新真正的崛起，必须依靠自身实力，培育创新氛围，打造创新体系，实现创新成果突破。从全球行业发展的商业模式来看，买买买的模式一点问题都没有，但像辉瑞、强生、阿斯利康、诺和诺德这类医药行业领军巨头企业，在国际上有一席之地的医药企业，中国要不要出现？”　　今年4月，康方生物公布了上市后的首份年度成绩单。","content":"<html><body><div>Source: ForbesThe track of pharmaceutical innovation,<a href=\"https://laohu8.com/S/PFE\">Pfizer</a>、<a href=\"https://laohu8.com/S/JNJ\">Johnson Johnson</a>、<a href=\"https://laohu8.com/S/AZN\">AstraZeneca</a>、<a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a>With so many international giants, it may not be feasible to grind a sword in ten years.Xia Yu, founder and chairman of Akeso Biological Co., Ltd., told Forbes China: \"<a href=\"https://laohu8.com/S/600056\">China Pharmaceutical</a>The real rise of innovation must rely on its own strength, cultivate an innovative atmosphere, build an innovative system and achieve breakthroughs in innovative achievements. From the perspective of the business model of global industry development, there is no problem with the model of buying, buying, buying, but leading giants in the pharmaceutical industry such as Pfizer, Johnson & Johnson, AstraZeneca, and Novo Nordisk, pharmaceutical companies with a place in the world, does China want to appear? \"\"China should emerge.\" Xia Yu is firm, and these companies' own R&D and innovation capabilities are the key to becoming world-class leaders.<div><div><img src=\"http://n.sinaimg.cn/finance/crawl/324/w550h574/20210727/9053-eb59dd1acbf005315f9f014538a392da.jpg\"/></div></div>Xia Yu, founder and chairman of Akeso Biological Co., Ltd.Credit: DRHowever, where should Chinese pharmaceutical companies that can compete with or even surpass giants pin their hopes?In April this year, Akeso Bio announced its first annual report card after listing. The announcement shows that as of the end of 2020, Kangfang Biotech's other income and income exceeded 100 million yuan; R&D investment reached 764.5 million yuan.After ten years of entrepreneurship, Kangfang Bio has finally developed a pioneer track for the research and development of original antibody drugs in China: among more than 20 drugs under development, 6 bispecific antibodies are the world's first or advanced in progress, and a number of cutting-edge target drug candidates The research and development progress is leading the world, with more than 20 clinical research projects in clinical phase II and beyond, and the core world's first double antibody is about to be launched... A Chinese biotechnology company that has actually gone abroad through self-research and development has quietly risen.<div><div><img src=\"http://n.sinaimg.cn/finance/crawl/80/w550h330/20210727/0264-3242e677075ee7bd62b8859c7068fc7c.jpg\"/></div></div>The world's first dual antibody cadonilimabCredit: DR　　Buy, buy, buy model, you can't buy China's Pfizer and China's Johnson & JohnsonMore than ten years ago, Xia Yu, who had worked hard to live a comfortable and superior life in a foreign country, returned to China, and in the bustling crowd in Beijing, she came up with the idea of starting a business. As a Chinese, Xia Yu's first question is, does China need original new drugs? Can Chinese people only use outdated foreign drugs ten years ago for decades?\"Actually, if I do the same thing (pharmaceutical R&D) in the United States, I will probably not do it at a certain stage of R&D.\" Xia Yu further said: \"Because I myself know very well that the investment in production and commercialization and even clinical trials after R&D is too huge. But today, with the development of the domestic pharmaceutical industry, whether from the perspective of capital market development or the support of industrial policies, China actually has the possibility to capture the global industry highland.\"Of course, participating in global competition, for Chinese pharmaceutical companies, a natural shortcoming is their late start and the overall development level of the industry is relatively backward. \"But just because there is a gap doesn't mean that we can't lead the world in some fields, some directions and some stages.\"Xia Yu is very clear that there are two ways to start a business in the pharmaceutical industry. One way is original research and development, using the company's own internal research and development strength to obtain competitive innovative drugs; Another way is to improve the company's R&D pipeline through external introduction.Ten years ago, the research and development of new drugs in China's pharmaceutical industry at that time could be described as \"poor and white\". Xia Yu still chose the original road.Even in recent years, with the return of a group of returnees, it has actually led to the return of individual advanced technologies. However, Xia Yu has been thinking and practicing how to drive the overall pharmaceutical industry to deepen its construction in China and how to establish a truly advanced R&D system in China. Without rushing for a moment, or even sacrificing the opportunity to produce advanced products, Xia Yu led Kangfang Biotech to invest a lot of energy at the beginning of its establishment to create an integrated R&D system internally.Only under such an innovative R&D system, with this will and ideal to grow and achieve industrialization from the source of R&D, will China's Pfizer and China's Johnson & Johnson appear in the future.<div><div><img src=\"http://n.sinaimg.cn/finance/crawl/40/w550h290/20210727/55da-1b43fa5d55b5db075d491294cb78bfd6.png\"/></div></div>Exterior view of Akeso Biotech Guangzhou baseCredit: DRSince its establishment in 2012, Akeso Bio has started from the highest-end source scientific research and innovation, and has been deployed at various industrial stages of production, commercialization and clinical, focusing on the development of the world's most cutting-edge tumor immunotherapy antibodies. At present, Akeso Bio has developed more than 20 innovative drug candidates, of which 13 innovative antibody new drugs are in the clinical research stage.\"In fact, it is an understandable business model not to make original new drugs. The only thing I think is wrong is that this matter has become the Red Sea, and it will be terrible for anything to enter the Red Sea.\" In China, drug regulation is facing An industrial reality is that even in 2016, the total R&D investment of national pharmaceutical companies is still less than that of the world's largest pharmaceutical companies.\"On the one hand, it is necessary to form the soil to cultivate industrial development; on the other hand, it is necessary to establish a competitive mechanism for survival of the fittest. The current pharmaceutical giants in the United States are also the result of survival of the fittest after experiencing industrial development and market competition. In China, such a scene will appear in the future.\" Xia Yu said.　　Ice and fire, the double-edged sword of capitalEven in the past two years, with the reform of the new stock listing system of the Hong Kong Stock Exchange and the introduction of the registration system in science and technology innovation board, it has provided new financing opportunities and more opportunities for pharmaceutical companies with different market orientations, different investor compositions, and different considerations of entry and exit mechanisms. Multiple choices. What remains unchanged is that the business model of entrepreneurship must be able to stand the test of the ability to maintain and increase the value of capital.Xia Yu recalled that in the early days of starting a business, if we really couldn't get the financial support of the capital market at that time, we might have survived through other means, but what is certain is that it is far from possible to achieve the current rapid development. In fact, a big role of capital is to help and accelerate the development of enterprises, so that enterprises can concentrate more on building senior innovation competitiveness in a competitive environment. \"　　<a href=\"https://laohu8.com/S/V03.SI\">Startups</a>The business model selected at each stage of development will have different manifestations at different stages of development.At the beginning of the business in 2012, drug innovation companies were not as sought after in the capital market as they are now. In order to survive and continue to develop, at the end of 2015, Xia Yu decided to license an innovative product of Akeso Biotech to the giant<a href=\"https://laohu8.com/S/MRK\">Merck & Co</a>。 \"I think in terms of business model, it must be a decision that is conducive to the long-term development of the company at that moment and supports our long-term development.\" On the other hand, this is the first innovative antibody drug independently developed by a local company in China that is authorized to the international TOP5 pharmaceutical giant, and it has also become one of the landmark events for China's innovative drug industry to truly go international and be internationally recognized. It has also allowed Kangfang Bio to enter the world stage of drug innovation for the first time.<div><div><img src=\"http://n.sinaimg.cn/finance/crawl/117/w550h367/20210727/b886-3bb61d586babf8c3cb5f2b87668503b0.jpg\"/></div></div>Production workshopCredit: DR\"Actually, I understand the capital market very well. In the early stage of starting a business, we spent a lot of time developing the platform, so we have gained a lot of achievements on the current platform. Nowadays, Kangfang, while efficiently promoting the clinical development of the existing pipeline, will focus more on the world's cutting-edge target drugs in product development. Because we already have a good product foundation and development experience, we have also been recognized by investors. But if I take investors' money to do innovative research and development for 10 years without any products, which investor can agree? \"If the birth of a new drug is a relay race for companies in the industrial chain, Xia Yu is determined to do a marathon.　　From studying overseas alone to returning to China to start a business, the market value is 50 billionA noteworthy phenomenon is that among the emerging innovative companies in the pharmaceutical industry, nearly 20% of the founders are women. Having accumulated senior experience in biopharmaceutical research and development, as an expert in antibody drug research and development, Xia Yu decided to return to China to start a business, and founded Kangfang Bio with three other returnees. As the chairman of the board, Xia Yu is the only woman in the management team.Xia Yu said: \"Women are more tolerant, women are more tenacious, persistent and persistent in one thing.\"\"But any perfection is relative, and there is no perfect person for entrepreneurship.\"Just as Xia Yu first decided to return to China to start a business, even with the support of her daughter's family, she still had to face the puzzlement around her. As a mother, shouldn't she accompany her daughter wholeheartedly at the critical stage of her growth? As a woman, why do you have to toss the so-called career in a comfortable middle age?With the sting of incomprehension, Xia Yu and her daughter transformed and grew up together. Now, my daughter says that her mother is the person she admires most.At this time, it has been more than ten years since Xia Yu founded Kangfang Bio alone.Following the official listing of Akeso Biotech on the Hong Kong Stock Exchange in 2020, the total market value once hit 55 billion Hong Kong dollars.Looking back on my youth, Xia Yu, who was born as a schoolmaster, said, \"I went abroad as soon as I graduated from college. At that time, I got a scholarship by myself, and I ran abroad without a few dollars. When I went abroad, it was really a world of difference from that at home. I was very uneasy at that time, and I didn't know what would happen next.\"In the following 20 years, Xia Yu worked in Sino-US Guanke Biology,<a href=\"https://laohu8.com/S/PDLI\">PDL BioPharma</a>, Bayer in Germany, CrownBio and other multinational pharmaceutical companies held management positions, and after completing postdoctoral research at the University of Glasgow in the United Kingdom, he conducted scientific research at the University of Louisville School of Medicine in the United States; While serving as senior vice president of Sino-US Guanke Biotechnology, he played a decisive role in developing and executing the company's strategy and establishing a joint venture with Pfizer.<div><div><img src=\"http://n.sinaimg.cn/finance/crawl/462/w550h712/20210727/7570-3cd7c1d54dc532007a1a67b35d002611.jpg\"/></div></div>Dr. Xia YuCredit: DRIn the founding team, Xia Yu is responsible for the company's overall strategic planning, business and scientific development direction. Xia Yu said: \"At the moment of enterprise development, what is needed is the courage to make a decision and the pressure and responsibility of decision-making. It really tests the leader's foresight and control of enterprise development.\"After achieving fruitful results in the \"original R&D route\" campaign, Xia Yu now leads the next challenge that Akeso biotech will face: product commercialization, from biotech to biopharma.In Xia Yu's view, \"Some companies may have made it very clear from the beginning of their business that they do what they are good at not involving production or future commercialization. This is also a good business model. But there are some companies, such as Akeso Bio, in fact, I have not set limits for the future. As long as conditions permit and are in line with the company's development strategy, we will push forward.The first condition, for example, I have enough talents and abilities to do both production and commercialization, which requires a larger enterprise development goal to promote it. In addition, as a founder, I should also have this ideal, which I think is very important. Because the more we reach the stage of production and commercialization, the more uncontrollable it is in a sense, and courage is necessary. \"Knowing that there are tigers in the mountains, I prefer to go to the tiger mountains. This is Xia Yu's persistence and tenacity.<div><div><img src=\"\"/></div><div>Massive information and accurate interpretation, all in<a href=\"https://laohu8.com/S/SINA\">SINA</a>Finance APP</div></div>Editor in charge: Liu Wanli SF014</div></body></html>","source":"sina","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Forbes China's exclusive interview with Xia Yu, Chairman of Akeso Biotech: Take a trip to Hushan Mountain</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nForbes China's exclusive interview with Xia Yu, Chairman of Akeso Biotech: Take a trip to Hushan Mountain\n</h2>\n<h4 class=\"meta\">\n\n财经自媒体2021-07-27 17:40\n\n</h4>\n</header>\n<article>\n<html><body><div>Source: ForbesThe track of pharmaceutical innovation,<a href=\"https://laohu8.com/S/PFE\">Pfizer</a>、<a href=\"https://laohu8.com/S/JNJ\">Johnson Johnson</a>、<a href=\"https://laohu8.com/S/AZN\">AstraZeneca</a>、<a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a>With so many international giants, it may not be feasible to grind a sword in ten years.Xia Yu, founder and chairman of Akeso Biological Co., Ltd., told Forbes China: \"<a href=\"https://laohu8.com/S/600056\">China Pharmaceutical</a>The real rise of innovation must rely on its own strength, cultivate an innovative atmosphere, build an innovative system and achieve breakthroughs in innovative achievements. From the perspective of the business model of global industry development, there is no problem with the model of buying, buying, buying, but leading giants in the pharmaceutical industry such as Pfizer, Johnson & Johnson, AstraZeneca, and Novo Nordisk, pharmaceutical companies with a place in the world, does China want to appear? \"\"China should emerge.\" Xia Yu is firm, and these companies' own R&D and innovation capabilities are the key to becoming world-class leaders.<div><div><img src=\"http://n.sinaimg.cn/finance/crawl/324/w550h574/20210727/9053-eb59dd1acbf005315f9f014538a392da.jpg\"/></div></div>Xia Yu, founder and chairman of Akeso Biological Co., Ltd.Credit: DRHowever, where should Chinese pharmaceutical companies that can compete with or even surpass giants pin their hopes?In April this year, Akeso Bio announced its first annual report card after listing. The announcement shows that as of the end of 2020, Kangfang Biotech's other income and income exceeded 100 million yuan; R&D investment reached 764.5 million yuan.After ten years of entrepreneurship, Kangfang Bio has finally developed a pioneer track for the research and development of original antibody drugs in China: among more than 20 drugs under development, 6 bispecific antibodies are the world's first or advanced in progress, and a number of cutting-edge target drug candidates The research and development progress is leading the world, with more than 20 clinical research projects in clinical phase II and beyond, and the core world's first double antibody is about to be launched... A Chinese biotechnology company that has actually gone abroad through self-research and development has quietly risen.<div><div><img src=\"http://n.sinaimg.cn/finance/crawl/80/w550h330/20210727/0264-3242e677075ee7bd62b8859c7068fc7c.jpg\"/></div></div>The world's first dual antibody cadonilimabCredit: DR　　Buy, buy, buy model, you can't buy China's Pfizer and China's Johnson & JohnsonMore than ten years ago, Xia Yu, who had worked hard to live a comfortable and superior life in a foreign country, returned to China, and in the bustling crowd in Beijing, she came up with the idea of starting a business. As a Chinese, Xia Yu's first question is, does China need original new drugs? Can Chinese people only use outdated foreign drugs ten years ago for decades?\"Actually, if I do the same thing (pharmaceutical R&D) in the United States, I will probably not do it at a certain stage of R&D.\" Xia Yu further said: \"Because I myself know very well that the investment in production and commercialization and even clinical trials after R&D is too huge. But today, with the development of the domestic pharmaceutical industry, whether from the perspective of capital market development or the support of industrial policies, China actually has the possibility to capture the global industry highland.\"Of course, participating in global competition, for Chinese pharmaceutical companies, a natural shortcoming is their late start and the overall development level of the industry is relatively backward. \"But just because there is a gap doesn't mean that we can't lead the world in some fields, some directions and some stages.\"Xia Yu is very clear that there are two ways to start a business in the pharmaceutical industry. One way is original research and development, using the company's own internal research and development strength to obtain competitive innovative drugs; Another way is to improve the company's R&D pipeline through external introduction.Ten years ago, the research and development of new drugs in China's pharmaceutical industry at that time could be described as \"poor and white\". Xia Yu still chose the original road.Even in recent years, with the return of a group of returnees, it has actually led to the return of individual advanced technologies. However, Xia Yu has been thinking and practicing how to drive the overall pharmaceutical industry to deepen its construction in China and how to establish a truly advanced R&D system in China. Without rushing for a moment, or even sacrificing the opportunity to produce advanced products, Xia Yu led Kangfang Biotech to invest a lot of energy at the beginning of its establishment to create an integrated R&D system internally.Only under such an innovative R&D system, with this will and ideal to grow and achieve industrialization from the source of R&D, will China's Pfizer and China's Johnson & Johnson appear in the future.<div><div><img src=\"http://n.sinaimg.cn/finance/crawl/40/w550h290/20210727/55da-1b43fa5d55b5db075d491294cb78bfd6.png\"/></div></div>Exterior view of Akeso Biotech Guangzhou baseCredit: DRSince its establishment in 2012, Akeso Bio has started from the highest-end source scientific research and innovation, and has been deployed at various industrial stages of production, commercialization and clinical, focusing on the development of the world's most cutting-edge tumor immunotherapy antibodies. At present, Akeso Bio has developed more than 20 innovative drug candidates, of which 13 innovative antibody new drugs are in the clinical research stage.\"In fact, it is an understandable business model not to make original new drugs. The only thing I think is wrong is that this matter has become the Red Sea, and it will be terrible for anything to enter the Red Sea.\" In China, drug regulation is facing An industrial reality is that even in 2016, the total R&D investment of national pharmaceutical companies is still less than that of the world's largest pharmaceutical companies.\"On the one hand, it is necessary to form the soil to cultivate industrial development; on the other hand, it is necessary to establish a competitive mechanism for survival of the fittest. The current pharmaceutical giants in the United States are also the result of survival of the fittest after experiencing industrial development and market competition. In China, such a scene will appear in the future.\" Xia Yu said.　　Ice and fire, the double-edged sword of capitalEven in the past two years, with the reform of the new stock listing system of the Hong Kong Stock Exchange and the introduction of the registration system in science and technology innovation board, it has provided new financing opportunities and more opportunities for pharmaceutical companies with different market orientations, different investor compositions, and different considerations of entry and exit mechanisms. Multiple choices. What remains unchanged is that the business model of entrepreneurship must be able to stand the test of the ability to maintain and increase the value of capital.Xia Yu recalled that in the early days of starting a business, if we really couldn't get the financial support of the capital market at that time, we might have survived through other means, but what is certain is that it is far from possible to achieve the current rapid development. In fact, a big role of capital is to help and accelerate the development of enterprises, so that enterprises can concentrate more on building senior innovation competitiveness in a competitive environment. \"　　<a href=\"https://laohu8.com/S/V03.SI\">Startups</a>The business model selected at each stage of development will have different manifestations at different stages of development.At the beginning of the business in 2012, drug innovation companies were not as sought after in the capital market as they are now. In order to survive and continue to develop, at the end of 2015, Xia Yu decided to license an innovative product of Akeso Biotech to the giant<a href=\"https://laohu8.com/S/MRK\">Merck & Co</a>。 \"I think in terms of business model, it must be a decision that is conducive to the long-term development of the company at that moment and supports our long-term development.\" On the other hand, this is the first innovative antibody drug independently developed by a local company in China that is authorized to the international TOP5 pharmaceutical giant, and it has also become one of the landmark events for China's innovative drug industry to truly go international and be internationally recognized. It has also allowed Kangfang Bio to enter the world stage of drug innovation for the first time.<div><div><img src=\"http://n.sinaimg.cn/finance/crawl/117/w550h367/20210727/b886-3bb61d586babf8c3cb5f2b87668503b0.jpg\"/></div></div>Production workshopCredit: DR\"Actually, I understand the capital market very well. In the early stage of starting a business, we spent a lot of time developing the platform, so we have gained a lot of achievements on the current platform. Nowadays, Kangfang, while efficiently promoting the clinical development of the existing pipeline, will focus more on the world's cutting-edge target drugs in product development. Because we already have a good product foundation and development experience, we have also been recognized by investors. But if I take investors' money to do innovative research and development for 10 years without any products, which investor can agree? \"If the birth of a new drug is a relay race for companies in the industrial chain, Xia Yu is determined to do a marathon.　　From studying overseas alone to returning to China to start a business, the market value is 50 billionA noteworthy phenomenon is that among the emerging innovative companies in the pharmaceutical industry, nearly 20% of the founders are women. Having accumulated senior experience in biopharmaceutical research and development, as an expert in antibody drug research and development, Xia Yu decided to return to China to start a business, and founded Kangfang Bio with three other returnees. As the chairman of the board, Xia Yu is the only woman in the management team.Xia Yu said: \"Women are more tolerant, women are more tenacious, persistent and persistent in one thing.\"\"But any perfection is relative, and there is no perfect person for entrepreneurship.\"Just as Xia Yu first decided to return to China to start a business, even with the support of her daughter's family, she still had to face the puzzlement around her. As a mother, shouldn't she accompany her daughter wholeheartedly at the critical stage of her growth? As a woman, why do you have to toss the so-called career in a comfortable middle age?With the sting of incomprehension, Xia Yu and her daughter transformed and grew up together. Now, my daughter says that her mother is the person she admires most.At this time, it has been more than ten years since Xia Yu founded Kangfang Bio alone.Following the official listing of Akeso Biotech on the Hong Kong Stock Exchange in 2020, the total market value once hit 55 billion Hong Kong dollars.Looking back on my youth, Xia Yu, who was born as a schoolmaster, said, \"I went abroad as soon as I graduated from college. At that time, I got a scholarship by myself, and I ran abroad without a few dollars. When I went abroad, it was really a world of difference from that at home. I was very uneasy at that time, and I didn't know what would happen next.\"In the following 20 years, Xia Yu worked in Sino-US Guanke Biology,<a href=\"https://laohu8.com/S/PDLI\">PDL BioPharma</a>, Bayer in Germany, CrownBio and other multinational pharmaceutical companies held management positions, and after completing postdoctoral research at the University of Glasgow in the United Kingdom, he conducted scientific research at the University of Louisville School of Medicine in the United States; While serving as senior vice president of Sino-US Guanke Biotechnology, he played a decisive role in developing and executing the company's strategy and establishing a joint venture with Pfizer.<div><div><img src=\"http://n.sinaimg.cn/finance/crawl/462/w550h712/20210727/7570-3cd7c1d54dc532007a1a67b35d002611.jpg\"/></div></div>Dr. Xia YuCredit: DRIn the founding team, Xia Yu is responsible for the company's overall strategic planning, business and scientific development direction. Xia Yu said: \"At the moment of enterprise development, what is needed is the courage to make a decision and the pressure and responsibility of decision-making. It really tests the leader's foresight and control of enterprise development.\"After achieving fruitful results in the \"original R&D route\" campaign, Xia Yu now leads the next challenge that Akeso biotech will face: product commercialization, from biotech to biopharma.In Xia Yu's view, \"Some companies may have made it very clear from the beginning of their business that they do what they are good at not involving production or future commercialization. This is also a good business model. But there are some companies, such as Akeso Bio, in fact, I have not set limits for the future. As long as conditions permit and are in line with the company's development strategy, we will push forward.The first condition, for example, I have enough talents and abilities to do both production and commercialization, which requires a larger enterprise development goal to promote it. In addition, as a founder, I should also have this ideal, which I think is very important. Because the more we reach the stage of production and commercialization, the more uncontrollable it is in a sense, and courage is necessary. \"Knowing that there are tigers in the mountains, I prefer to go to the tiger mountains. This is Xia Yu's persistence and tenacity.<div><div><img src=\"\"/></div><div>Massive information and accurate interpretation, all in<a href=\"https://laohu8.com/S/SINA\">SINA</a>Finance APP</div></div>Editor in charge: Liu Wanli SF014</div></body></html>\n<div class=\"bt-text\">\n\n\n source：<a href=\"https://finance.sina.com.cn/chanjing/cyxw/2021-07-27/doc-ikqcfnca9352486.shtml\">财经自媒体</a>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/bc7ad619aa7e42a7db4703997b65806b","relate_stocks":{"09926":"康方生物"},"source_url":"https://finance.sina.com.cn/chanjing/cyxw/2021-07-27/doc-ikqcfnca9352486.shtml","is_english":false,"share_image_url":"https://static.laohu8.com/b0d1b7e8843deea78cc308b15114de44","article_id":"2154992231","content_text":"来源：福布斯\n　　医药创新这个赛道，辉瑞、强生、阿斯利康、诺和诺德等国际巨头林立，十年磨一剑也未必可行。\n　　康方生物有限公司创始人、董事长夏瑜向福布斯中国表示：“中国医药创新真正的崛起，必须依靠自身实力，培育创新氛围，打造创新体系，实现创新成果突破。从全球行业发展的商业模式来看，买买买的模式一点问题都没有，但像辉瑞、强生、阿斯利康、诺和诺德这类医药行业领军巨头企业，在国际上有一席之地的医药企业，中国要不要出现？”\n　　“中国应该出现。”夏瑜很坚定，而这些企业自身的研发创新能力是企业成为世界级领导者的关键。\n\n\n\n　　康方生物有限公司创始人、董事长夏瑜\n　　图片来源：DR\n　　只是，能与巨头比肩甚至超越巨头的中国医药企业，应该把希望寄托于哪里？\n　　今年4月，康方生物公布了上市后的首份年度成绩单。公告显示，截至2020年底，康方生物其他收入及收益超1亿元；研发投入达到7.645亿元。\n　　创业十年，康方生物终于开拓出一条中国原创抗体药物研发的先行者赛道：20多款在研药物中，6款全球首创或进度领先的双特异性抗体，多款最前沿靶点候选药物研发进度全球领先，超过20个临床研究项目在临床II期及往后阶段，核心全球首创双抗即将上市……一家实打实通过自我研发走出国门的中国生物科技公司悄然崛起。\n\n\n\n　　全球首创双抗cadonilimab\n　　图片来源：DR\n　　买买买模式，买不来中国的辉瑞、中国的强生\n　　十几年前，在异国他乡已打拼出安逸优越生活的夏瑜回国，在北京熙熙攘攘的人群中，冒出创业的念头。作为一名中国人，夏瑜首先想到的问题是，中国是不是需要原创新药？中国人难道只能数十年如一日地用国外十年前的过时药？\n　　“其实，如果我在美国做同样的事情（医药研发），我很有可能做到一个研发某个阶段就不做了。”夏瑜进一步表示：“因为我自己也很清楚，研发后的生产和商业化，甚至临床实验的投入实在太巨大了。但时至今日，随着国内医药行业的发展，无论是从资本市场发展还是产业政策的支持来看，中国其实已经拥有了去攻占全球行业高地的可能。”\n　　当然，参与全球竞争，对于中国医药企业来说，一个天然短板是起步晚、行业整体发展水平相对落后。“但有差距并不代表我们自己在某一些领域、某一些方向、某一些阶段上，就没有办法做到世界领先。”\n　　夏瑜很清楚，踏入医药行业创业有两条路可以选，一条路是原创研发，利用公司自己内部的研发实力获得具有竞争力的创新药；另一条路则是通过外部引进的方式来完善公司的研发管线。\n　　在十年前，当时中国医药行业的新药研究和开发可谓“一穷二白”。夏瑜还是选择了原创的路。\n　　即便近年来，随着一批海归创业者的回归，事实上带动了个体先进技术的回归。但如何带动整体医药行业在中国去深耕建设，如何在中国建立真正先进的研发体系，夏瑜一直在思考与实践。没有急于一时，甚至是牺牲了生产先进产品的时机，夏瑜带领康方生物选择在创立之初，就投入巨大精力，在内部创建一体化的研发体系。\n　　只有在这样的创新研发体系下，具有这种意愿和理想去成长，从研发源头一直做到产业化，未来中国的辉瑞、中国的强生才会出现。\n\n\n\n　　康方生物广州基地外景\n　　图片来源：DR\n　　2012年成立至今，康方生物从最高端的源头科研创新入手，一直到生产、商业化和临床各产业阶段布局，专注开发全球最前沿的肿瘤免疫治疗抗体。目前，康方生物已经开发了超过20个创新候选药物，其中13款创新抗体新药处于临床研究阶段。\n　　“其实不做原创新药也是无可厚非的一种商业模式。唯一我认为出问题的地方是，这个事情变成了红海，而任何事情走入红海就会很可怕。”在中国，药品监管面临的一个产业现实是，即使到了2016年，全国制药企业研发投入总和仍不及全球最大制药企业一家。\n　　“一方面要形成培育产业发展的土壤，另一方面一定要建立优胜劣汰的竞争机制。美国现在的医药巨头，也是经历了产业发展和市场竞争后优胜劣汰的结果。在中国，未来也要出现这样的景象。”夏瑜说。\n　　冰火两重天，资本双刃剑\n　　即便近两年间，随着港交所新股上市制度改革及科创板注册制的推出，给面向市场不同、投资人构成不同、进退出机制考量不同的医药企业，提供了全新的融资机会和更多元的选择。不变的是，创业的商业模式都要能经得起资本保值增值能力的考验。\n　　夏瑜回顾，在创业初期，如果我们当时真的是得不到资本市场的资金支持，可能也会通过其它方式存活下来，但是可以肯定的是，远不可能实现现在的飞速发展。资本其实很大的一个作用是助力，加快企业的发展速度，让企业在竞争的环境中可以更加专心地构建资深的创新竞争力。”\n　　创业公司在每一个发展阶段所选择的商业模式在不同的发展阶段会有不同的体现。\n　　在创业之初2012年，药物创新企业在资本市场并不像现在这样备受追捧。为了生存和继续发展，2015年底，夏瑜决定将康方生物的一个创新产品授权给巨头默沙东。“我觉得从商业模式来讲，在那个时刻一定是一个利于公司长期发展的决定，支撑了我们走向长期发展。”另一方面，这是中国第一款本土企业自主研发的创新抗体药物授权给国际TOP5的制药巨头，也成为中国创新药物产业真正走向国际，并受到国际认可的一个标志性事件之一，也让康方生物在首次登上了药物创新的世界舞台。\n\n\n\n　　生产车间\n　　图片来源：DR\n　　“其实我很理解资本市场。在创业前期我们花了大量的时间做平台的开发，所以才有现在平台上很多的成果收获。时下的康方，我们在高效推进现有管线的临床发展的同时，在产品开发会更聚焦世界前沿的靶点药物。因为我们已经有了很好的产品基础、开发经验，也获得了投资人的认可。但如果我在什么产品都没有的情况下，拿着投资人的钱去做10年的创新研发，试问哪个投资人能答应？”\n　　如果说一种新药的诞生是产业链上各个公司的接力赛，夏瑜决心做的是一场马拉松。\n　　从只身海外求学到归国创业市值500亿\n　　一个值得关注的现象是，在医药行业崭露头角的创新公司中，近20%的创始人是女性。积累了资深的生物药物研究开发经历，作为抗体药物研发专家，夏瑜决定归国创业，与其他3名海归人士创立康方生物。夏瑜作为董事长，是管理团队中唯一一名女性。\n　　夏瑜说：“女性更包容，女性更有韧劲，对一件事情的执着和坚持。”\n　　“但是任何的完美都是相对的，创业没有完美人设。”\n　　就像夏瑜最初决定回国创业，即便得到了女儿家人的支持，仍要面对周遭的不解。已为人母，在女儿成长的关键阶段难道不应该全身心陪伴？作为一名女性，为什么在生活舒适的中年还要再去折腾所谓的事业？\n　　带着不被理解的刺痛，夏瑜和女儿一起蜕变、成长。如今，女儿说，妈妈是自己最崇拜的人。\n　　此时，距离夏瑜一腔孤勇创立康方生物已逾十年。\n　　继2020年康方生物在港交所正式挂牌上市，如今总市值一度冲击550亿港元。\n　　回顾曾经的青春岁月，学霸出身的夏瑜说，“大学一毕业我就出国了。那个时候完全是靠自己拿到一份奖学金，都没揣几块钱就跑出国门，到国外一看跟国内真的是天壤之别。当时很忐忑，不知道接下来会怎么样。”\n　　此后20年间，夏瑜在中美冠科生物、PDL BioPharma、德国拜耳、CrownBio等跨国制药公司担任管理职务，并在英国格拉斯哥大学完成博士后研究工作后，于美国路易斯维尔大学医学院进行科学研究；在担任中美冠科生物技术高级副总裁期间，为公司制定和执行战略以及与辉瑞建立合资企业方面发挥了决定性作用。\n\n\n\n　　夏瑜博士\n　　图片来源：DR\n　　在创始团队中，夏瑜负责公司总体战略规划、业务和科学发展方向。夏瑜说：“在企业发展的抉择时刻，需要的就是拍板的勇气，承担决策的压力和责任。确实考验领导者的深谋远虑和对企业发展的把控。”\n　　在“原创研发路线”战役取得丰硕成果之后，如今夏瑜带领着康方生物要面临的下一个挑战：产品商业化，从biotech走向为biopharma。\n　　在夏瑜看来，“有一些公司可能从创业之初就非常明确说不涉及生产，不涉及未来的商业化，就做自己擅长的事，这也是一种很好的商业模式。但有一些企业，比如康方生物，其实我是没有为未来设限的，只要条件允许，符合公司发展战略，我们就推进。\n　　第一个条件，比如说我是有足够的人才和能力去把生产和商业化都做起来，这就需要一个更大的企业发展目标来推动了。另外，作为创始人，我也要有这个理想，我觉得这非常重要。因为越做到生产和商业化这个阶段，某种意义上说不可控性更强，勇气是必须要有的。”\n　　明知山有虎，偏向虎山行。这就是夏瑜的执着与坚韧。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：刘万里 SF014","news_type":1,"symbols_score_info":{"09926":1}},"isVote":1,"tweetType":1,"viewCount":1987,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":1,"xxTargetLangEnum":"ORIG"},"commentList":[],"hasMoreComment":false,"orderType":2}